MOLECULAR RECOGNITION OF MATERIALS

• US 20080242552A1
• Filed: 07/24/2007
• Published: 10/02/2008
• Est. Priority Date: 06/05/2001
• Status: Active Grant

• Current Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Original Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Inventors: Belcher, Angela M.
• Granted Patent: US 8,372,949 B2
• Time in Patent Office: Days
• US Class Current: 506/9
• CPC Class Codes: G01N 33/543 with an insoluble carrier for immobilising immunochemicals
• CPC Class Codes: G01N 33/68 involving proteins, peptides or amino acids involving lipoproteins G01N33/92
• CPC Class Codes: G01N 33/6803 General methods of protein analysis not limited to specific proteins or families of proteins

Abstract

The present invention includes methods for selective binding of inorganic materials and the compositions that made up of the selecting agent and the target materials. One form of the present invention is a method for selecting crystal-binding peptides with binding specificity including the steps of contacting one or more amino acid oligomers with one or more single-crystals of a semiconductor material so that the oligomers may bind to the crystal and eluting the bound amino acid oligomers from the single-crystals.

Claims

1-180. -180. (canceled)

181. A composition comprising one or more peptide binding sequences, wherein at least one peptide binding sequence is selective for a target crystalline face of a target crystal.

182. The composition according to claim 181, wherein the peptide binding sequence comprises one or more peptide binding sequences selected from a phage display library or a combinatorial library.

183. The composition according to claim 181, wherein the peptide binding sequence comprises one or more peptide binding sequences which are between about 7 to 15 amino acids in length.

184. The composition according to claim 181, wherein the peptide binding sequence is part of a virus which comprises DNA which encodes the peptide binding sequence.

185. The composition according to claim 181, wherein the peptide binding sequence is part of a bivalent synthetic peptide.

186. The composition according to claim 181, wherein the peptide binding sequence is part of a virus or bacteriophage.

187. The composition according to claim 181, wherein the peptide binding sequence is part of a p3 or p8 modified bacteriophage.

188. The composition according to claim 181, wherein the target crystal is a single crystal.

189. The composition according to claim 181, wherein the target crystal is part of a heterostructured crystal surface.

190. The composition according to claim 181, wherein the target crystal is an inorganic crystal.

191. The composition according to claim 181, wherein the target crystal is a semiconductor crystal.

192. The composition according to claim 181, wherein the target crystal is a III-V semiconductor crystal or a II-VI semiconductor crystal.

193. The composition according to claim 181, wherein the target crystal is a magnetic crystal.

194. The composition according to claim 181, wherein the target crystal is a mineral or an optical material.

195. The composition according to claim 181, wherein the target crystal is a nanoparticle.

196. The composition according to claim 181, wherein the target crystal has an oxide surface.

197. The composition according to claim 181, wherein the target crystal is gallium arsenide, indium phosphide, gallium nitride, zinc sulfide, cadmium sulfide, aluminum arsenide, gallium stibinide, aluminum gallium arsenide, aluminum stibinide, aluminum arsenide, cadmium selenide, zinc selenide, cadmium telluride, zinc selenide, indium arsenide, silicon, FePd, cobalt, manganese, lithium niobate, iron oxide, silica or calcium carbonate.

198. The composition according to claim 181, wherein the target crystal is a single crystal.

199. The composition according to claim 181, wherein the peptide binding sequence is fused to a protein, and the target crystal is a single crystal.

200. The composition according to claim 181, wherein the peptide binding sequence is part of a virus and is between about 7 to 15 amino acids in length, and wherein the target crystal is a semiconductor crystal.

201. The composition according to claim 181, wherein the peptide binding sequence is bound to a crystal.

202. The composition according to claim 181, wherein the peptide binding sequence is bound to a nanoparticle, a surface, or a patterned surface.

203. The composition according to claim 181, wherein the peptide binding sequence is part of a bivalent synthetic peptide which is bound to a surface and to a nanoparticle.

204. A composition comprising one or more peptide binding sequences, wherein at least one peptide binding sequence selectively binds a target crystalline face of a target crystal.

205. A composition comprising one or more viruses, wherein the virus comprises one or more peptide binding sequences, wherein at least one peptide binding sequence selectively binds a target crystal.

206. A composition comprising one or more viruses, wherein the virus comprises one or more peptide binding sequences, wherein at least one peptide binding sequence is selective for a target inorganic crystalline face of a target inorganic crystal, and the virus is bound to the target single inorganic crystal.

207. The composition according to claim 206, wherein the virus is a bacteriophage, the peptide binding sequence comprises 7 to 15 amino acids, and the target inorganic crystal is a semiconductor crystal.

208. The composition according to claim 206, wherein the virus is bound to a nanoparticle through the peptide binding sequence.

209. The composition according to claim 206, wherein the virus is bound to a nanoparticle and to a surface of the target inorganic crystal.

210. A method of selecting a composition comprising one or more peptide binding sequences, wherein at least one peptide binding sequence is selective for a target crystalline face of a target crystal, the method comprising the step of:

contacting a library of peptide binding sequences with a target crystalline surface structure so that selective binding between the peptide binding sequences and the target crystalline surface structure is achieved with face specificity.

211. The method according to claim 210, wherein the peptide binding sequences are parts of viruses.

212. The method according to claim 210, wherein the peptide binding sequences are parts of p3 or p8 modified viruses.

213. The method according to claim 210, wherein the target crystalline surface structure is a semiconductor surface structure.

214. A method of selecting a composition comprising one or more viruses, wherein the virus comprises one or more peptide binding sequences, wherein at least one peptide binding sequence is selective for a target crystal, the method comprising the step of:

contacting a library of viruses comprising peptide binding sequences with one or more target crystalline surface structures so that selective binding between the peptide binding sequences and the target crystalline surface structures is achieved.

215. The method of claim 214, wherein the binding is face selective.

216. The method of claim 214, wherein the binding is composition selective.

217. The method according to claim 214, wherein the peptide binding sequences are parts of p3 or p8 modified viruses.

218. The method according to claim 214, wherein the target crystalline surface structure is an inorganic surface structure.

219. The method according to claim 214, wherein the target crystalline surface structure is a semiconductor surface structure.